Results 71 to 80 of about 5,308 (216)
Drug crystallization – implications for topical and transdermal delivery [PDF]
, 2016 INTRODUCTION: Crystallization of actives in skin following topical application was suggested by studies in the 1950s and 1960s but is poorly understood.
Hadgraft, J, Lane, ME
core +1 more source
Journal of Ophthalmology, Volume 2026, Issue 1, 2026.Background Diabetic retinopathy (DR) is a progressive microvascular complication related to diabetes mellitus and remains a profound cause of vision impairment and blindness globally. In addition to its ocular manifestations, DR is increasingly recognized as a main risk factor for systemic diseases, including cardiovascular and neurodegenerative ...
Zixuan Huang +3 more
wiley +1 more source
Innovative transdermal drug delivery systems: Benefits, challenges, and emerging application
BMEMat, Volume 3, Issue 4, December 2025.The graphical abstract illustrates the diverse nanostructures employed in transdermal drug delivery systems, highlighting their unique mechanisms to penetrate the intricate layers of skin. It provides a detailed representation of the skin's complex anatomy, emphasizing the challenges posed by its barrier properties.
Syed Waqas Ali Shah +9 more
wiley +1 more source
Comparative blanching activities of some topical corticosteroid containing lotions [PDF]
, 1981 The blanching activities of Betnovate and Celestoderm-V lotions (betamethasone-17-valerate, 0,1%) and Diprosone lotion (betamethasone dipropionate, 0,55%) were determined by measuring their ability to cause blanching of human skin after topical ...
Haigh, J M, Kanfer, I, Meyer, I
core +1 more source
Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease
Responsive Materials, Volume 3, Issue 4, November 2025.This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang +11 more
wiley +1 more source
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy [PDF]
, 2018 FKBP51 (FK506-binding protein 51) is a known co-chaperone and regulator of the glucocorticoid receptor (GR), which usually attenuates its activity. FKBP51 is one of the major GR target genes in skin, but its role in clinical effects of glucocorticoids is
Baida, Gleb +8 more
core +2 more sources
Clinical Pharmacology in Drug Development, Volume 14, Issue 10, Page 742-753, October 2025.Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano +8 more
wiley +1 more source
Drug Design, Development and Therapy, 2016 Liu QY, He MM, Shi H, et al. Drug Des Devel Ther. 2015;9: 2527–2535. In “Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials” published ...
Liu QY +8 more
doaj
A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials [PDF]
, 2017 There is no treatment for the myelin loss in multiple sclerosis, ultimately resulting in the axonal degeneration that leads to the progressive phase of the disease.
Agresti, C. +11 more
core +2 more sources
Assessment of topical corticosteroid preparations: the human skin-blanching assay [PDF]
, 1984 (From the introduction) Since the introduction of topical corticosteroid formulations, their use has become widespread, being prescribed for a large variety of dermatological conditions.
Haigh, J M, Kanfer, I
core +1 more source